Prävention des Schlaganfalls
durch Blutdrucksenkung

J Schrader; S Lüders

doi:10.1055/s-0031-1286392

DMW – Klinischer Fortschritt, Table of Contents

Dtsch Med Wochenschr 2011; 136(40): 2045-2049
DOI: 10.1055/s-0031-1286392

Prävention & Versorgungsforschung | Review article

Versorgungsforschung, Hypertensiologie
© Georg Thieme Verlag KG Stuttgart · New York

Prävention des Schlaganfalls durch Blutdrucksenkung

Prevention of stroke by blood pressure loweringJ. Schrader¹ , S. Lüders¹

¹St. Josefs-Hospital Cloppenburg

Abstract

Schlüsselwörter

Hypertonie - Schlaganfall - antihypertensive Therapie - Prävention - Blutdruckvariabilität - Zielblutdruck

Keywords

hypertension - stroke - antihypertensive therapy - prevention - blood pressure variability - target blood pressure

Full Text

References

Literatur

1 Beckett N S, Peters R, Fletscher A E. et al . Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008; 358 1887-1898
2 Cushman W C, Evans G W. et al . ACCORD Study Group: Effects of intensive blodd-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010; 362 1575-1595
3 Dahlöf B, Sever P S, Poulter N R. et al . Prevention of cardiovaskular events with an an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):a multicentre randomised controlled trial. Lancet. 2005; 366 895-906
4 Deutsche Hochdruckliga e. V. DHL® – Deutsche Hypertonie Gesellschaft: Leitlinien zur Therapie der arteriellen Hypertonie. Heidelberg; 2008
5 Elliot W J, Meyer P M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007; 369 201-207
6 Eriksson S E, Olsson J E. Survival and recurrent strokes in patients with different subtypes of stroke: a fourteen-year follow-up study. Cerebrovasc Dis. 2001; 12 171-180
7 Giles M F, Rothwell P M. Risk of stroke early after transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol. 2007; 6 1063-1072
8 Lindholm L H, Carlberg B, Samuelssson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005; 366 1545-1553
9 Lüders S. Drug therapy for the secondary prevention of stroke in hypertensive patients. Current issues and options. Drugs. 2007; 67 955-963
10 MacMahon S, Rodgers A. Primary and secondary prevention of stroke. Clin Exp Hypertens. 1996; 18 537-546
11 Messerli F H, Mancia G, Conti C R. et al . Dogma disputed: can aggressively lowering blood pressure in hypertensive patients coronary artery disease be dangerous?. Ann Intern Med. 2006; 144 884-893
12 Messerli F H, Bangalore S, Ruschitzka F. Angiotensin receptor blockers: baseline therapy in hypertension?. Eur Heart J. 2009; 30 2427-2430
13 O’Donell M J, Xavier D, Liu L. et al . Risk factors for ischemic and intracerebral haemorrhagic stroke in 22 Countries (the INTERSTROKE study): a case-control study. Lancet. 2010; 376 112-123
14 Progress Collaborative Group . Randomised trial of a perindopril-based blood-pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001; 358 1033-1041
15 Psaty B M, Lumley T, Furberg C D. et al . Health outcomes associated with various antihypertensive therapies used first line agents: a network meta-analysis. JAMA. 2003; 289 2534-2544
16 Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events. Stroke. 2003; 34 2741-2749
17 Rothwell P M, Howard S C, Dolan E. et al . Prognostic significance of visit-to-visit variability, maximun systolic blood pressure, and episodic hypertension. Lancet. 2010; 375 895-905
18 Schrader J, Lüders S, Kulschewski A. et al . Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005; 36 1218-1226
19 Schrader J. Blutdrucksenkung nach Schlaganfall. Dtsch Med Wochenschr. 2006; 131 758-761
20 Skoog I, Lernfelt B, Landahl S. et al . 15-year longitudinal study of blood pressure and dementia. Lancet. 1996; 347 1141-1145
21 Tu J V. Reducing the global burden of stroke. Lancet. 2010; 376 74-75
22 Webb A J, Fischer U, Mehta Z, Rothwell P M. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet. 2010; 375 906-915
23 Williams B, Lacy P S, Thom S M. et al . Differential impact of blodd pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006; 113 1213-1225
24 Yusuf S, Diener H C, Sacco R L. et al . Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008; 359 1225-1237
25 Yusuf S, Hawken S, Ôunpuu S. et al on behalf of the INTERHEART study investigatorsE . ffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEARTstudy): case-control study. Lancet. 2004; 364 937-952

Prof. Dr. Joachim Schrader

St. Josefs-Hospital

Krankenhausstr. 13

49661 Cloppenburg

Phone: 04471/16-2951

Fax: 04471/16-2970

Email: j.schrader@kh-clp.de